Spyre Therapeutics, Inc. SYRE NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score

35/100

2/6 Pass

SharesGrow Intrinsic Value

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Spyre Therapeutics, Inc. (SYRE) has a negative trailing P/E of -115.5, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -0.87%.

Criteria proven by this page:

VALUE (19/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E -115.5); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -0.87%); analyst consensus target implies downside from the current price ($51.00, 26.1%).
Trailing Earnings Yield -0.87% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings.
Analyst consensus target $51.00 (-26.1% downside) — analysts see meaningful downside risk at the current price level.

Overall SharesGrow Score: 34/100 with 2/7 criteria passed.

SharesGrow 7-Criteria Score

35/100

SG Score

View full scorecard →

✗

VALUE

19/100

Price-to-Earnings & upside

Proven by this page

✓

FUTURE

64/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

✓

HEALTH

100/100

Debt-to-Equity & liquidity

→ Health

✗

MOAT

12/100

→ Income

✗

GROWTH

15/100

→ Income

—

INCOME

N/A

No coverage

Valuation Snapshot — SYRE

Valuation Multiples

P/E (TTM)-115.5

Forward P/EN/A

PEG RatioN/A

Forward PEGN/A

P/B Ratio25.06

P/S Ratio34.57

EV/EBITDA-17.0

Per Share Data

EPS (TTM)$-0.45

Book Value / Share$2.07

Revenue / Share$0.26

FCF / Share$-0.49

Yields & Fair Value

Earnings Yield-0.87%

Dividend Yield0.00%

Analyst Target$51.00 (-26.1%)

Historical Valuation

Year	P/E (TTM)	PEG Ratio	P/B Ratio	P/S Ratio	Dividend Yield
2016	-2.0	-0.02	0.68	9.20	-
2017	-3.0	0.16	1.63	15.72	-
2018	-3.5	-0.19	2.31	40.11	-
2019	-3.1	-0.21	4.06	0.00	-
2020	-5.2	0.14	3.00	0.00	-
2021	-4.7	0.14	3.72	16.67	-
2022	-0.5	0.71	0.75	16.28	-
2023	-0.4	-0.01	0.81	167.52	-
2024	-5.3	0.06	2.11	0.00	-
2025	-73.0	1.94	15.85	0.00	-

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2016	$-55.40	$4.63M	$-21.7M	-468.8%
2017	$-45.01	$5.21M	$-27.24M	-523.3%
2018	$-53.25	$3.89M	$-44.35M	-1140.6%
2019	$-61.23	$0.00	$-78.25M	-
2020	$-37.89	$0.00	$-80.89M	-
2021	$-25.02	$18.74M	$-65.8M	-351.1%
2022	$-24.86	$2.33M	$-83.82M	-3598.8%
2023	$-46.15	$886K	$-338.79M	-38238.1%
2024	$-0.56	$0.00	$-208.02M	-
2025	$-1.98	$0.00	$-155.2M	-

Analyst Estimates

Year	EPS (Avg)	EPS Range	Revenue (Avg)	Revenue Range	Analysts
2026	$-2.92	$-3.65 – $-2.47	$88.6K	$88.6K – $88.6K	10
2027	$-3.13	$-3.61 – $-2.40	$166.67K	$166.67K – $166.67K	9
2028	$-3.32	$-4.56 – $-2.42	$200K	$200K – $200K	7
2029	$-3.67	$-3.67 – $-3.67	$37.66M	$37.66M – $37.66M	2
2030	$-3.87	$-3.87 – $-3.87	$92.32M	$92.32M – $92.32M	5